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Abstract
Titin truncating variants are a well-established cause of cardiomyopathy; however, the role of titin missense variants is less 
well understood. Here we describe the generation of a mouse model to investigate the underlying disease mechanism of a 
previously reported titin A178D missense variant identified in a family with non-compaction and dilated cardiomyopathy. 
Heterozygous and homozygous mice carrying the titin A178D missense variant were characterised in vivo by echocardiogra-
phy. Heterozygous mice had no detectable phenotype at any time point investigated (up to 1 year). By contrast, homozygous 
mice developed dilated cardiomyopathy from 3 months. Chronic adrenergic stimulation aggravated the phenotype. Targeted 
transcript profiling revealed induction of the foetal gene programme and hypertrophic signalling pathways in homozygous 
mice, and these were confirmed at the protein level. Unsupervised proteomics identified downregulation of telethonin and 
four-and-a-half LIM domain 2, as well as the upregulation of heat shock proteins and myeloid leukaemia factor 1. Loss of 
telethonin from the cardiac Z-disc was accompanied by proteasomal degradation; however, unfolded telethonin accumulated 
in the cytoplasm, leading to a proteo-toxic response in the mice.We show that the titin A178D missense variant is pathogenic 
in homozygous mice, resulting in cardiomyopathy. We also provide evidence of the disease mechanism: because the titin 
A178D variant abolishes binding of telethonin, this leads to its abnormal cytoplasmic accumulation. Subsequent degradation 
of telethonin by the proteasome results in proteasomal overload, and activation of a proteo-toxic response. The latter appears 
to be a driving factor for the cardiomyopathy observed in the mouse model.
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Introduction
Titin is the largest protein, with a size of up to 3.7 megadal-
tons. It is expressed specifically in striated muscle tissues 
[32]. Each titin molecule spans half a sarcomere, which 
is the contractile unit responsible for force generation in 
cardiomyocytes and skeletal myotubes: the N-terminus of 
titin is anchored at the Z-disc, while its C-terminal end is 
embedded in the M-band. Consistent with its enormous 
size, numerous proteins have been identified as titin bind-
ing partners. Examples include alpha-actinin, cysteine rich 
protein 3 (Csrp3, also called muscle LIM protein, MLP) 
and telethonin (also called Tcap) at the Z-disc; and myosin 
binding protein C, myosin and myomesin in more distal 
regions (for review see [15]). Importantly, several titin 
binding partners, including four-and-a-half-LIM-domain 
1 and 2 (Fhl1 and Fhl2), cardiac ankyrin repeat protein 
(Ankrd1), heat shock proteins, obscurin and calpain-3, 
have been implicated in diverse signalling pathways [36]. 
This suggests that titin does not merely play a structural 
role as a ‘molecular ruler’ of the sarcomere [55] and mod-
ulator of passive stiffness [41], but it is also an important 
hub, integrating distinct signalling networks required for 
striated muscle adaptation (reviewed in [34]). In support 
of this, titin features a kinase domain [45] and is also sub-
jected to post-translational modifications that modulate its 
functions (reviewed in [33]).
Titin is encoded by the gene TTN, comprising of 364 
exons. Historically, TTN has been implicated in inher-
ited skeletal or cardiac muscle diseases, mainly through 
genome-wide linkage approaches [14]. Advances in high 
throughput sequencing have made TTN more accessible for 
genetic analyses in clinical practice, revealing that up to 
25% of familial dilated cardiomyopathy (DCM) cases are 
associated with truncating variants in TTN [21].
Due to the large size of the gene, individually rare, 
even private, missense variants in titin are seen extremely 
frequently in cohort databases, such as GnomAD [28]. 
TTN missense variants are detected in both cardiomyopa-
thy cases and controls, hence it is assumed that the large 
majority do not cause disease [54]. As a result, TTN mis-
sense variants are generally ignored in clinical genetic 
reports, as their functional evaluation is so challenging 
that they are rarely actionable [27]. Nevertheless, using 
a combination of genome-wide linkage and next genera-
tion sequencing, we identified the titin missense variant 
A178D as the most likely cause of cardiac disease in a 
family affected by autosomal dominant left ventricular 
non-compaction (LVNC) and DCM [19]. In this family, 
9 individuals carried the variant, and 4 of these had fea-
tures of pronounced hypertrabeculation and mild DCM. 
A further 3 had only DCM and the remaining 2 had 
pronounced hypertrabeculation without DCM. Of note, 8 
out of 9 affected individuals were clinically stable and did 
not progress into heart failure.
Here we present a unique mouse model carrying this vari-
ant, and show that, even in isolation, this variant is sufficient 
to cause cardiac disease in homozygous animals. Moreover, 
our molecular analyses give insight into the underlying dis-
ease mechanisms associated with this variant, namely the 
loss and proteasomal degradation of telethonin from the 
Z-discs of cardiomyocytes, the downregulation of Fhl2 and 
the induction of a proteo-toxic response. To our knowledge, 
this is the first mouse model for cardiac disease caused by 
a titin missense variant with unique insights into disease 
mechanisms.
Methods
An expanded Methods section can be found in the Electronic 
Supplementary Material online.
Ethical statement
Animal studies have been performed in accordance with 
the ethical standards laid down in the 1964 Declaration 
of Helsinki and its later amendments. Experimental pro-
cedures were performed in accordance with the Direc-
tive 2010/63/EU and UK Home office guidelines (project 
licences 30/2966, 30/2977, P37BA1809 and P572C7345) 
and approved by the respective institutional ethical review 
boards.
Animals were housed in specific pathogen free condi-
tions, with the only reported positives on health screen-
ing over the entire time course of these studies being for 
Tritrichomonas sp. and Entamoeba spp. All animals were 
housed in social groups (apart from single housing with 
enrichment for chronic adrenergic stimulation experiments), 
provided with food and water ad libitum and, maintained on 
a 12 h light:12 h dark cycle (150–200 lx cool white LED 
light, measured at the cage floor).
Phenotyping experiments and offline analysis were 
performed blinded, and treatment groups were randomly 
assigned to animals, with no animals excluded from the 
study. All in vivo phenotyping studies were carried out using 
littermates of adult male mice. Both males and females were 
used for in vitro studies. Animals were sacrificed by cervical 
dislocation and death confirmed by cessation of circulation.
Generation of the mice and genotyping
Ttn c. 533 C > A single base pair substitution was introduced 
into mouse embryonic stem cells using CRISPR-Cas9 medi-
ated homology-directed repair. A target site for CRISPR 
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mutagenesis (5′- AGC TCT TCC AAC GCT GTT GG-3′), 
with minimal predicted off target sites (http://crisp or.tefor 
.net) was selected, immediately downstream of the codon 
encoding Alanine-178, on the antisense strand relative to 
Ttn transcription. Two complementary oligos encoding this 
CRISPR target were annealed and cloned into the BbsI site 
of pX330-Puro, encoding a CAG-Cas9 expression cassette 
and a U6-promoter driven single guide-RNA (sgRNA) scaf-
fold, together with a puromycin resistance cassette. A 138 
nt single-stranded-oligodeoxynucleotide (ssODN), serving 
as a homology repair template, was synthesized (Eurogen-
tec). This contained the desired A178D change and a silent 
3 base pair change to introduce a de novo DdeI restriction 
site to facilitate the genotyping of the recombinant allele 
(Fig. S1a, b). Mouse C57BL/6N embryonic stem cells (ES, 
JM8F6) were electroporated with 5 µg of the pX330-Puro 
plasmid and 200 pmol of the ssODN using the Neon trans-
fection system (Life Technologies, 3 × 1400 V, 10 ms). 
After 24 h, 48 h of selection in 600 ng/µl puromcyin was 
applied, and resistant ES cells were clonally expanded and 
genotyped using primers (5′- CCG AGA CAG CAC CAC CCA 
ACTT-3′ and 5′-TTG ACC TTA GCT CAG GCG AGC ACC -3′) 
to amplify the target region. Successful targeting was first 
established by DdeI digestion, followed by confirmation by 
Sanger sequencing. ES cell clones harbouring the A178D 
mutation homozygously were microinjected into albino 
C57BL/6 J blastocysts. The resulting chimeras were bred 
with wild-type C57BL/6 J mice and germline transmission 
of the A178D Ttn allele confirmed.
Both heterozygous (HET) and homozygous (referred to 
as A178D) titin A178D mice were viable and fertile. The 
expression of the mutated allele A178D was confirmed at 
the mRNA level by reverse transcriptase-PCR and Sanger 
sequencing (Fig. S1c), as well as at the protein level by mass 
spectrometry (Fig. S1d). Animals were backcrossed onto 
C57BL/6J (Envigo) for at least 2 generations before generat-
ing wild-type and heterozygous littermates and for at least 
5 generations before generating wild-type and homozygous 
littermates for all WT and A178D studies.
Ultrasound echocardiography
General anaesthesia was initially induced using 4% isoflu-
rane by inhalation (Piramal Critical Care) in an anaesthesia 
chamber. Animals were then placed onto a heated platform, 
and the anaesthesia was maintained continuously with the 
usage of 1–1.5% isoflurane. Body temperature of the animals 
was maintained at 37 ºC, and echocardiography was per-
formed with a 22–55 MHz linear array transducer using the 
Vevo 2100 ultrasound system (Visualsonics). Data acquisi-
tion was normally completed within 30 min of anaesthesia, 
followed by offline analysis blinded to the genotype and the 
treatment group, if applicable.
Left ventricular haemodynamic measurements
To measure left ventricular (LV) haemodynamic index, gen-
eral anaesthesia was induced as above. The animal was sur-
gically prepared to allow insertion of a 1.4 F Millar Mikro-
tip catheter (SPR-671) into the LV of the animal via the 
carotid artery and intubation of another infusion catheter of 
an electronic auto-pump into the jugular vein. Animals were 
maintained under 1.25–1.5% isoflurane for 15 min to allow 
baseline recordings, before administration of dobutamine 
(Hameln Pharmaceuticals Ltd) through the jugular vein 
(4 ng per g bodyweight per min, followed by 16 ng per g 
bodyweight per min) for the contractile reserve assessment.
Administration of drugs via osmotic minipumps
Animals of each genotype were randomised into treatment 
and control groups. A short surgical procedure for implan-
tation was carried out. Briefly, anaesthesia was induced as 
described above, and each animal was given a single dose 
of Vetergesic (buprenorphine hydrochloride, Ceva Animal 
Health Ltd) at 50 µg  kg−1 body weight by sub-cutaneous 
injection for pain relief before the procedure. Micro-osmotic 
pumps (model 1002, ALZET) were implanted subcutane-
ously into continuously anaesthetised animals (with 1.5% 
isoflurane) via a midscapular incision. In the treatment 
group, the α- and β-adrenergic agonists, isoprenaline and 
phenylephrine (Iso/PE; in hydrochloride forms, Sigma-
Aldrich) were delivered to the animals via minipumps that 
released both substances at a rate of 15 mg  kg−1 body weight 
per day in 0.9% NaCl (Vetivex 1, from Dechra) for a total of 
14 days. In the control group, animals were implanted with 
minipumps containing 0.9% NaCl alone for the same time 
course. The response of adrenergic challenge was assessed 
by echocardiography 13 days post-surgery, followed by 
organ harvest on day 14 to allow downstream analysis.
For tandem ubiquitin-binding entities (TUBE) assay 
(see below) and cryo-sections, epoxomicin (APexBio), was 
administered at 0.5 mg  kg−1 bodyweight per day in 10% 
dimethyl sulfoxide in 0.9% NaCl for 7 days using micro-
osmotic pumps (model 1007D, ALZET). Vehicle (10% 
dimethyl sulfoxide in 0.9% NaCl) served as control.
Western blotting
Western blotting was performed as described [12] with anti-
bodies listed in Table S11.
Please note some loading controls (Gapdh or Ponceau 
S) may be shown in multiple figures, as the same mem-
branes were probed for more than one protein. This applies 
to Figs. 4b, 5a, 6a, S16–S20, S23, S30–S35.
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Mass spectrometry
Protein fractionation into cytoplasmic and myofilament 
fractions was done according to [59]. Sample preparation, 
data acquisition and analysis see Supplementary Methods.
Cardiomyocyte isolation, contractility, calcium 
transients, size and immunofluorescence
Adult mouse left ventricular cardiomyocytes were isolated 
and sarcomere shortening measurements were obtained 
using an IonOptix µstep apparatus according to the manu-
facturer’s operating instructions as previously described 
[52]. For details see Supplementary Methods.
High Resolution Episcopic Microscopy (HREM)
Tissue and data processing for HREM was performed as 
previously described [44]. For details see Supplementary 
Methods.
Statistics
Values are given as mean ± standard error of mean (SEM) 
if normally distributed or as median ± SEM if not, or 
as violin or box and whisker plots displaying median, 
25th/75th percentile, and whiskers as minimum/maxi-
mum values. To compare two unpaired sample groups, 
data was tested for normality using the Shapiro-Wilk test. 
Normally distributed data was analysed by Student’s t test, 
and data that was not, was analysed by Mann–Whitney U 
test (GraphPad Prism 7.03).
When there were more than 2 groups and data were 
normally distributed, one-way ANOVA followed by 
Tukey’s post-hoc test was used (GraphPad Prism 7.03). 
If data were not normally distributed, p values were 
obtained by Kruskal–Wallis followed by Wilcoxon rank 
sum test with Bonferroni correction (R version 3.6.0), or 
by Kruskal–Wallis followed by Dunn’s multiple compar-
ison’s test. Haemodynamic data were analysed by two-
way-ANOVA with Bonferroni correction (GraphPad Prism 
7.03). Violin plots were generated with GraphPad Prism 
8.4.1.
To compensate for the likely clustering of data from cells 
from the same mouse, the Student’s t test using hierarchical 
clustering method described by Sikkel et al. was used to 
assess any difference in cardiomyocyte size, contractility and 
calcium measurements [50].
Annotations used: n.s. – not significant (p > 0.05), 
*p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001 versus 
WT; n indicates number of animals in each group. p < 0.05 
was considered significant.
Results
Introduction of A178D does not affect titin 
expression or localisation
We first assessed whether the A178D missense variant 
change in our mouse model had any consequences on titin 
protein expression or localisation. No changes in titin tran-
script or protein levels were observed (Figs. S2 and S3a). 
Likewise, there was no alteration in isoform composition or 
global phosphorylation, the latter as assessed by ProQDia-
mond stain (Figs. S2b, S3c). Moreover, the T2 band, indica-
tive of protein turnover [32], was similarly abundant between 
homozygous A178D and WT hearts (Figs. S2b, c, S3b). The 
titin epitope harbouring the variant (Z1Z2), localised nor-
mally to the Z-disc in homozygous A178D mice (Fig. S4). 
Likewise, titin epitopes close to the Z-disc (T12) and in the 
M-band (m8) were normally localised (Fig. S4). Finally, at 
the ultra-structural level, assessed by electron microscopy, 
sarcomeric and Z-disk appearance were normal and Z-disc 
width was unchanged in homozygous A178D hearts (Fig. 
S5). These observations suggest that the A178D variant has 
no effect on gross sarcomeric organisation of the heart.
Heterozygous titin A178D mice display no cardiac 
abnormalities
As the titin A178D variant caused autosomal dominant car-
diomyopathy in patients [19], we first assessed the cardiac 
phenotype of heterozygous (HET) mice by echocardiogra-
phy. Their hearts were structurally indistinguishable from 
wild-type (WT) littermates at all time points investigated 
(3 month, 6 month, 1 year, Fig. S6a and Table S1). Moreo-
ver, heart weight to tibial length was normal (Fig. S6b), and 
no differences were observed during invasive LV haemody-
namic measurements, either at baseline or upon adrenergic 
stimulation (Fig. S6c, Table S2).
Homozygous titin A178D mice show features 
of DCM but not of LVNC
The cardiac function of the homozygous A178D mice 
(referred to as A178D) in comparison to their WT litter-
mates was investigated by echocardiography. A178D mice 
had mildly reduced systolic function (as shown by a reduc-
tion in fractional shortening) as well as enlarged systolic 
and diastolic dimensions (Fig. 1a, Table S3). By contrast, 
their diastolic wall thickness and left ventricular mass 
were not altered (Table S3) and heart weight normalised 
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to tibial length was normal (Table S3). Thus, these mice 
show features typical of mild DCM.
We next probed for abnormal trabeculation, a hall-
mark of disease in a sub-set of patients carrying the TTN 
A178D variant [19]: High-resolution episcopic micros-
copy (HREM) suggested that A178D hearts were more 
rounded, with the lumens of both LV and RV appearing 
more open (Fig. S7a–n). However, morphometric analysis 
of lumen volume and heart shape was not significantly 
different between A178D and WT mice. In addition, tra-
beculation in basal sections of A178D hearts appeared 
more pronounced, although this was also not statistically 
significant (Fig. S7o). Thus, there was no clear evidence 
of a LVNC phenotype in A178D mice.
Titin is expressed not only in the heart, but also in skeletal 
muscle and pathogenic variants in titin are also associated 
with skeletal muscle pathologies [7]. However, there was no 
evidence of abnormalities in the skeletal muscle of A178D 
mice (Fig. S8).
Ageing does not aggravate the phenotype of A178D 
mice
To test whether the phenotype of A178D becomes more 
pronounced with age, we aged a cohort of A178D mice 
to 1 year. No premature deaths were observed. On echo-
cardiography, mice had mildly enlarged LV cavity dimen-
sions in both systole and diastole (LVESD and LVESSD, 
Fig. 1  Cardiac phenotype of 
the A178D mice. a Echocar-
diographic measurements: frac-
tional shortening, end-systolic 
and end-diastolic dimensions 
are shown (Student’s t-test, 
n = 21/17 WT/A178D, all 
males, age 99 ± 1 days). For 
cohort characteristics and a 
wider set of echocardiographic 
parameters please refer to 
Table S3. b Effect of chronic 
adrenergic stimulation by Iso/
PE infusion on cardiac perfor-
mance in WT and A178D mice. 
Hypertrophic response to Iso/
PE as indicated by LV mass is 
similar between both geno-
types (left). Systolic function 
of A178D hearts was reduced 
upon Iso/PE treatment (right). 
For cohort characteristics and a 
wider set of echocardiographic 
parameters please refer to 
Table S5; (n = 10/9 sham/Iso/
PE; Kruskal–Wallis followed 
by Wilcoxon rank sum test 
with Bonferroni correction, all 
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Fig. S9, Table S4). The visual trend towards reduced frac-
tional shortening did not reach significance. Hence, aged 
A178D did not have an aggravated cardiac phenotype, 
rather it appeared milder than in young mice.
Adrenergic challenge aggravates the phenotype 
of A178D mice
We next compared the response of young A178D and WT 
mice to chronic adrenergic challenge, which has similar 
physiological consequences to trans-aortic constriction, 
but is more refined for the animals. Infusion with isopren-
aline and phenylephrine (Iso/PE) led to a robust hyper-
trophic response in both WT and A178D hearts (Fig. 1b, 
Table S5). There was a tendency of reduced systolic func-
tion upon treatment, which was more profound in A178D 
hearts (Fig. 1b, Table S5).
In summary, homozygous A178D mice display a mild 
DCM phenotype without pronounced hypertrophy or 
abnormal trabeculation under baseline conditions, hence 
reflecting some, but not all aspects of the human cardio-
myopathy phenotype. The observed in vivo phenotype 
does not aggravate with age. Their hypertrophic response 
to chronic adrenergic challenge did not differ from that 
of WT mice. However, challenged homozygous A178D 
hearts had a trend towards aggravated decline of cardiac 
function.
Altered cellular characteristics in isolated A178D 
cardiomyocytes
To assess the functional consequences of the A178D vari-
ant, we isolated adult mouse cardiomyocytes from WT and 
A178D hearts. Unloaded A178D cells had an approximate 
32% increase in cell area, driven by increases in both cell 
length and width (Figs. 2, S10, Table S6).
Next, contractility of isolated unloaded cells was investi-
gated upon pacing. All contraction parameters investigated 
were normal (Fig. S11a, Table S6). In agreement, measured 
calcium transients were normal (Fig. S11b, Table S7). These 
experiments suggest that the titin variant does not alter the 
contractile properties of isolated, unloaded cells.
We further assessed passive tension in demembranised, 
loaded fibre preparations (Fig. S12, Table S8). Overall pas-
sive tension, as well as titin-derived tension, were similar in 
WT and A178D mice, suggesting that the A178D change 
does not affect titin’s role in controlling compliance of the 
heart.
Changes in the transcriptome profile of A178D mice
We next used transcriptome profiling to gain insight into the 
molecular changes underlying the titin A178D phenotype. 
We isolated RNA from 3 WT and 4 A178D hearts and ana-
lysed gene expression by RNAseq. 295 transcripts were up- 
and 374 were downregulated (Fig. S13, Table S9). In keep-
ing with previous studies, genes known to be upregulated in 
Fig. 2  Altered cellular char-
acteristics in A178D hearts. 
a Image of isolated cardio-
myocytes from WT and A178D 
hearts, stained with wheat 
germ agglutinin (WGA). b, 
c Quantification of cellular 
dimensions: b cellular area, c 
left—cell length, right—cell 
width. Values of each measured 
cell are shown as individual 
data points, colour coded by 
the heart they are isolated from, 
means are indicated by black 
bar. (Total of 392/369 cells from 
12 independent isolations from 
4 female and 8 male mice each 
for WT/A178D, age: 128 ± 8 
days/132 ± 10 days WT/A178D; 
Student’s t test using hierarchi-
cal clustering see Methods). For 
size distribution per isolation 
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DCM, including Acta1 and Nppa [4, 20], were amongst the 
most upregulated genes (Fig. S13a). Gene set enrichment 
analysis identified ‘Proteasome’ to be the most significantly 
enriched pathway in A178D hearts (Fig. S13b, Table S10). 
Other enriched pathways were “Oxidative Phosphorylation”, 
“Butanoate Metabolism” and “Ribosome” (Table S10).
In agreement with the RNAseq data, a targeted approach 
revealed induction of the foetal gene programme in A178D 
hearts (induction of Nppa, Myh7, Acta1, Fig. 3a). Addition-
ally, a very modest, but statistically significant induction of 
Fhl1, Ankrd1 and Ankrd2 was observed, all transcripts impli-
cated in hypertrophic signalling. In the cohorts aged for 1 
year, heterozygous mice displayed no indication of changes 
in expression for any transcript. Aged homozygous A178D 
mice showed induction of the foetal gene programme and 
statistically significant induction of Ankrd1 (Fig. 3b). The 
expression of titin Z-disc binding partners muscle LIM pro-
tein (Csrp3) and telethonin (Tcap) was normal at the tran-
script level (Figs. 3, S2) in all cohorts investigated. Further, 
there was no evidence of induction of pro-fibrotic signalling. 
In support, histology of A178D hearts was indistinguishable 
from WT samples, and no prominent fibrosis was observed 
(Fig. S14).
We next investigated the molecular response to chronic 
adrenergic stimulation (Fig. S15). As expected, the Iso/PE 
treatment led to the induction of transcripts related to the 
foetal gene programme, hypertrophic signalling and fibrosis 
in both WT and A178D mice. In agreement with the ten-
dency towards worse performance of A178D hearts in vivo, 
there was a trend towards increased induction of these tran-
scripts in the Iso/PE treated A178D hearts compared to Iso/
PE treated WT hearts, reaching statistical significance for 
Nppa and Acta1.
In summary, A178D hearts have a molecular signature of 
cardiomyopathy, namely the induction of a foetal gene pro-
gramme, and this is aggravated upon adrenergic stimulation.
Consequences of titin A178D at the protein level
To validate the findings of the transcript analysis, we probed 
young adult A178D mice, aged HET and homozygous 
A178D mice, and young adult A178D mice that underwent 
adrenergic challenge for protein levels of selected markers 
at the protein level: beta-myosin (encoded by Myh7), as a 
marker of the foetal gene programme; Fhl1, Ankrd1 and 
Rcan1, as markers of hypertrophic signalling; and Csrp3, 
as a titin binding partner in the Z-disc (Table  1, Figs. 
S16–S20). Beta-myosin was significantly upregulated in 
aged A178D mice, Fhl1 was significantly upregulated in the 
A178D sham group, while Rcan1 and Csrp3 were signifi-
cantly upregulated in the A178D Iso/PE group. For Ankrd1, 
there was a visual trend of induction in aged A178D mice. 
These findings confirm that there was induction of the foetal 
gene programme and hypertrophic signalling at the protein 
level in our mouse model.
Unsupervised proteomics reveal insights 
into changes in the A178D hearts
To gain further insights into the underlying disease mech-
anisms in our mouse model, we performed unsupervised 
proteomics to compare WT and A178D hearts. Quantita-
tive comparison of myofilament protein fractions identified 
downregulation of telethonin and Fhl2 in A178D hearts, as 
well as upregulation of three heat shock proteins and mye-
loid leukaemia factor 1 (Mlf1) (Fig. 4a). We validated these 
results using Western blots, showing a 50% reduction in Fhl2 
protein levels in A178D mice, both in total protein lysates 
(Fig. 4b, c) and in the myofilament fraction (Fig. S21C). 
Likewise, Mlf1 protein levels were upregulated in the adr-
energic challenge cohort, both in the sham and in the Iso/PE 
group (Fig. S22). These experiments validate the findings 
from the proteomics approach for both proteins.
Loss of telethonin from the Z‑disc of A178D hearts
In agreement with the proteomics data, telethonin was strik-
ingly (> 90%) downregulated in A178D hearts (Fig. 5a, 
b), despite normal transcript levels (Fig. 3a). In WT adult 
mouse cardiomyocytes, telethonin co-localises with the titin 
Z1Z2 epitope at the Z-disc (Fig. 5c). By contrast, in A178D 
cardiomyocytes, the sarcomeric signal for telethonin at the 
Z-disc was completely abolished. This was confirmed using 
two antibodies that recognise different epitopes (Fig. 5c). 
Telethonin downregulation was also confirmed in homozy-
gous A178D aged mice and in A178D mice that underwent 
adrenergic challenge experiments (Fig. S23b–d).
Intriguingly, the small amount of remaining telethonin 
was not found in the myofilament fraction, but was re-dis-
tributed to the cytoplasmic protein fraction in A178D mice 
(Fig. 6), resulting in an approximately ninefold increase in 
cytosolic telethonin comparative to WT cytosolic levels. 
The protein was phosphorylated normally (Fig. S26a, b), 
but was polyubiquitinylated in A178D hearts (Fig. S23a), 
suggesting that it is degraded by the ubiquitin-proteasomal-
system (UPS). Likewise, Fhl2 was also polyubiquitinylated 
in A178D hearts (Fig. S21b). Treatment of A178D mice 
with the proteasomal inhibitor epoxomicin in vivo partially 
restored telethonin and Fhl2 signal in A178D hearts (Figs. 7 
and S24), adding confidence that the UPS is involved in the 
degradation of the proteins. 
Protein degradation can also be mediated by autophagy 
[43]. Of two autophagy-markers investigated, LC3-II, the 
lipidated form of LC3, was normal (data not shown) and 
p62 elevated significantly in aged HET and A178D mice 
(Fig. S25).
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Fig. 3  a Targeted assessment 
of transcriptional changes by 
qPCR for 3 month old A178D 
mice. All measurements are 
normalised to Gapdh. Signifi-
cant changes are observed in the 
hearts of A178D mice (Mann–
Whitney U test, WT: n = 10 
(4M/6F), age 114.2 ± 0.7 days; 
A178D n = 12 (6M/6F), age 
113.4 ± 0.5 days). b Targeted 
assessment of transcriptional 
changes by qPCR in 1 year old 
WT, Het and A178D mice. All 
measurements are normalised 
to Gapdh; Significant changes 
are observed in the hearts of 
A178D mice (Kruskal–Wallis 
followed by Dunn’s multiple 
comparison’s test, WT: n = 5, 
age 411 ± 3 days, HET n = 6, 
age 412 ± 2 days, A178D n = 6, 
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The complete loss of telethonin from the Z-disc was the 
most striking feature of mouse hearts carrying the A178D 
variant. Therefore, we explored telethonin-mediated func-
tions in A178D mice to determine if any of these were 
impaired. Telethonin has been suggested to be involved in 
p53 signalling, and lack of telethonin results in p53-mediated 
apoptosis [30]. However, p53 expression was normal at both 
transcript and protein levels in A178D hearts (Fig. S27a, 
b). In addition, most transcripts related to apoptosis were 
also normal in A178D hearts. This was true also for aged 
mice, or after chronic adrenergic stimulation (Fig. S27c, d). 
This is consistent with the observation that no replacement 
fibrosis (substituting apoptotic cardiomyocytes by fibrous 
tissue) was observed in these mice (Fig. S14). In addition, 
T-tubular organisation, linked to normal telethonin function 
[24], was unaltered in A178D mice (Fig. S26c). Hence, none 
of the known telethonin functions seemed affected in our 
mouse model.
Proteo‑toxic response in A178D hearts
With “proteasome” being the most upregulated pathway 
in our RNAseq analysis, incomplete clearance of cytosolic 
telethonin by the UPS could be an indicator of proteasomal 
overload. Consequently, accumulating mis-folded proteins 
could induce a proteo-toxic response [10]. In support of this, 
an upregulation of three heat shock proteins was detected in 
our proteomics dataset (Fig. 4a). Hence, we probed for the 
induction of the key players of the proteo-toxic response 
machinery. At transcript level, the only significant upregula-
tion was observed for Hspb1 and Hspb7 in A178D hearts in 
the sham-treated group of the adrenergic challenge experi-
ments (Fig. S28). At protein level, induction of a proteo-
toxic response was more clearly indicated by upregulation of 
its components in aged A178D hearts (Hsc70, αβ-crystallin 
and Hsp27, Figs. 8a, S29–34, Table 2). The response was 
even more prominent upon adrenergic challenge: Bcl2-asso-
ciated anthanogene (Bag3), Hsp70 and Hsp27 were strik-
ingly upregulated in Iso/PE treated A178D hearts compared 
to WT undergoing the same treatment (Figs. 8b, S29–S34, 
Table 2). 
In summary, telethonin was found to be lost from the 
Z-discs of titin A178D mice, however none of the known 
telethonin functions were affected in these mice. Further-
more, we demonstrated accumulation of the remaining tel-
ethonin in the cytoplasm, its ubiquitinylation and evidence 
of induction of a proteo-toxic response that was especially 
apparent upon additional stressors, such as ageing or adren-
ergic challenge.
Discussion
In this study, we have generated a novel mouse model for 
the TTN missense variant A178D, which was originally 
identified as the most likely cause of cardiomyopathy in a 
family affected by both DCM and LVNC [19]. Remarkably, 
homozygosity for a single amino acid change in a protein of 
approximately 34,350 residues results in a measurable car-
diac phenotype of reduced systolic function and mild dila-
tation as well as increased cardiomyocyte size. Moreover, 
while ageing did not aggravate the phenotype and we would 
expect a normal life-span of the mice, homozygous mice 
had an aggravated response to chronic adrenergic stimula-
tion. Taken together, this is a robust indication that the titin 
A178D missense variant is solely responsible for the DCM 
aspect of cardiomyopathy in the reported family.
Our molecular studies, combining –omics approaches and 
targeted analyses, identify the potential molecular mecha-
nisms underpinning the cardiomyopathy phenotype in this 
family (such as induction of transcripts related to the foetal 
gene programme) and provide further insights into disease 
pathways. However, despite the DCM phenotype, the gross 
performance of titin seemed to be unaffected by the mis-
sense variant: the titin protein has unchanged abundance 
and isoform composition and is normally incorporated into 
sarcomeres. Given the mild phenotype of our mouse model, 
it is no surprise that RNAseq identified only a modest num-
ber of differently expressed genes compared to other mouse 
Table 1  Summary of results 
from Western blots on the three 
different cohorts
Significant changes of homozygous A178D compared to WT (of same treatment group for Iso/PE chal-
lenge) are indicated; ↑ upregulation, n.s. not significant. No changes were observed in aged heterozygous 
mice
For original blots and quantifications see Figs. S16–20
Protein (Transcript) Figure 3 month old Aged (1 year old) Iso/PE challenge
Beta-myosin (Myh7) S16 n.s. ↑ n.s.
Fhl1 S17 Not detectable n.s. ↑ (sham)
Ankrd1 S18 Not quantifiable Not quantifiable n.s
Rcan1 S19 n.s. n.s. ↑ (Iso/PE)
Csrp3/MLP S20 n.s. n.s. ↑ (Iso/PE)
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models of cardiomyopathy [4, 10]. Likewise, the proteomics 
approach identified only 6 differentially expressed proteins.
Nevertheless, particularly the proteomics approach has 
revealed insights into the molecular changes driving disease 
in the model. Most strikingly, telethonin was downregulated 
in the A178D hearts. Telethonin is the only reported bind-
ing partner of the first two immunoglobulin domains of titin 
(Z1Z2), and the titin-telethonin interaction is the strongest 
known non-covalent protein–protein interaction [3]. Our 
previous work [19] has shown that A178D abolishes the 
titin-telethonin interaction in cells, and hence agrees with 
the observed loss of telethonin from the Z-discs of A178D 
mice. Titin Z1Z2, together with telethonin and Csrp3, was 
initially proposed to be a Z-disc-based mechano-sensor [29], 
but more recent work has suggested that Csrp3 is not an 
integral part of the Z-disc [13]; nevertheless, Csrp3 plays 
important roles in stress signalling [37]. In agreement with 
a functional titin Z1Z2—telethonin—Csrp3 complex, we see 
Fig. 4  a Volcano plot visualis-
ing unsupervised proteomics 
results (normalised by log2 
transformation followed by 
median subtraction in Perseus, 
followed by Student’s t test 
with permutation based FDR 
calculation, n = 6, age WT 
114 ± 1 days/A178D 113 ± 1 
days, 3M/3F). Significantly 
downregulated proteins are 
telethonin and Fhl2, signifi-
cantly upregulated proteins are 
αβ-crystallin (αβ-cryst), heat 
shock protein 27 (Hsp27), 
Dnaj homology subfamily B 
member (Dnajb6, another heat 
shock protein) and myeloid 
leukaemia factor 1 (Mlf1), all 
shown in red. b Representative 
Western blot demonstrating the 
downregulation of Fhl2 in total 
extracts of A178D mice. Gapdh 
serves as loading control. c 
Quantification of blot in panel 
B indicates downregulation of 
Fhl2 by approximately 50%; 
(mean ± SEM, n = 6, age WT 
114 ± 1 days/A178D 113 ± 1 
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aggravated upregulation of Csrp3 in the A178D mice (with 
strikingly reduced telethonin levels) under adrenergic stress.
We now further demonstrate that unbound telethonin 
translocates to the cytoplasm and undergoes degradation. 
However, even the striking loss of telethonin (> 90% in our 
model) might be expected to only have a mild phenotype in 
mice, since a global knock-out of telethonin has no cardiac 
baseline phenotype in unchallenged mice [30]. To our sur-
prise, none of the known telethonin features and suggested 
functions were affected in our model: our mouse model had 
normal passive stiffness [17], telethonin phosphorylation 
[5], normal T-tubular organisation [24], and no evidence of 
p53-mediated apoptosis [30].
Hence, a likely explanation could be that it is not the lack 
of telethonin at the Z-disc itself, but the remaining telethonin 
in the cytoplasm that is deleterious to the A178D hearts. 
Telethonin that is not complexed with titin is predicted to be 
unfolded [39] and cannot be recruited to the Z-disc. Instead 
it translocates to the cytoplasm, where it is likely to be rec-
ognised by small heat shock proteins (indicated by upregu-
lation of αβ-crystallin and Hsp27), which try to maintain 
telethonin in a folded state and if this fails, target the protein 
for degradation by the UPS [25]. Degradation of telethonin 
by the UPS is supported by: (i) the presence of a PEST 
sequence in telethonin (amino acids 106–130 [23]). These 
are sequences rich in proline (P), glutamic acid (E), serine 
(S), and threonine (T), associated with proteins that have a 
short intracellular half-life and assumed to act as a signal 
peptide for protein degradation [47]; (i) the observed enrich-
ment of a “Proteasome” gene set in our RNAseq dataset; (ii) 
Fig. 5  Loss of telethonin from 
the Z-discs of A178D hearts. 
a Protein destabilisation of 
telethonin in A178D hearts 
demonstrated by Western blot-
ting. GAPDH serves as loading 
control. b Quantification of 
telethonin depletion (to < 10% 
of WT levels) in A178D hearts, 
normalised to Gapdh protein 
(shown as mean ± SEM, Stu-
dent’s t test, n = 6, age 113 ± 1 
days, all males). c Loss of 
telethonin from cardiac Z-disc 
in A178D mice. Top: Isolated 
cardiomyocytes from WT and 
A178D mice were stained with 
an antibody recognising titin 
Z1Z2 epitope and telethonin; 
merged images: Z1Z2 green, 
telethonin red. Bottom: cells 
were stained with a different 
telethonin antibody and Z-disc 
marker α-actinin (merged 
images: telethonin green, 
α-actinin red). Age WT: 98 
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the partial restoration of sarcomeric telethonin and Fhl2 in 
A178D mice treated with the proteasome inhibitor epox-
omicin and (iii) the polyubiquitinylation of the protein in 
our mouse model, which we experimentally confirmed in a 
TUBE assay. However, the UPS fails to clear telethonin in 
the A178D mice to the cytoplasmic levels of WT mice. Such 
continuous demand on the UPS, as identified by upregula-
tion of transcripts related to the proteasome in the RNAseq 
data set, can result in overload of the proteasome and in the 
accumulation of unfolded proteins. Indeed, we did document 
an upregulation of the proteo-toxic response machinery, as 
indicated by induction of its components Bag3, Hsc70 and 
Hsp70.
The importance of the proteo-toxic response machin-
ery for cardiac integrity is clearly documented by human 
genetic data and experimental models: Human truncating 
variants in BAG3 as well as loss-of-function missense vari-
ants (e.g. E455K) can cause DCM [9, 11]. Cardiac-specific 
loss of Bag3 results in cardiomyopathy in mice [11], and 
myofibrillar disruption in human induced pluripotent stem 
cell derived cardiomyocytes [26]. Moreover, the contribu-
tion of a proteo-toxic response to cardiomyopathy has been 
documented for pathogenic variants in CSRP3 and MYBPC3 
through in vitro experiments and mouse models [10, 57].
How does this proteo-toxic response caused by UPS 
impairment result in cardiomyopathy? While the detailed 
mechanisms are not fully elucidated, three pathways have 
been proposed (reviewed in [49]): (i) under impaired UPS 
conditions, pro-hypertrophic and pro-apoptotic proteins may 
not be degraded and could accumulate, (ii) unfolded protein 
response may result in ER stress, upregulation of chaperones 
(heat shock proteins) and attenuation of protein synthesis, 
and (iii) UPS impairment may result in the activation of the 
autophagy-lysosomal pathway. Further work will focus on 
untangling these mechanisms.
Fhl2 does not bind titin at the affected titin Z1Z2 region, 
but in the more distal N2B region. Hence, its downregulation 
may be secondary, again possibly mediated through degra-
dation by the UPS (as evidenced by polyubiquitinylation in 
the TUBE assay and partial restoration upon epoxomicin 
treatment). Fhl2 is an anti-hypertrophic signalling mediator 
[40], acting through sequestration of Erk1/2 and calcineurin 
[22, 46], and is also thought to recruit metabolic enzymes 
to the sarcomere [35]. However, despite these key roles in 
the heart, its loss is tolerated in the unchallenged mouse 
heart [31].
As is true for all model systems, genetically modified 
mice have their limitations for studying human genetic 
Fig. 6  a Telethonin down-
regulation and re-distribution in 
A178D hearts: Myofilament and 
cytoplasmic protein fractions 
from WT and A178D hearts 
were blotted for telethonin 
(teleth). α-actinin served as 
loading control for the myofila-
ment fraction, Gapdh as loading 
control for the cytoplasmic 
fraction, respectively. In A178D 
hearts, no telethonin is detected 
in the myofilament fraction. 
In contrast, the remaining 
telethonin protein is enriched in 
the cytoplasmic fraction. (n = 6, 
3M/3F, age WT 114 ± 1 days, 
A178D 113 ± 1 days). b Quanti-
fication of telethonin accumula-
tion in the cytoplasm in A178D 
hearts, normalised to Gapdh 
protein (shown as mean ± SEM, 
Student’s t test, n = 5, 2M/3F, 
age WT 114 ± 1 days, A178D 
113 ± 1 days; the first two lanes 
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disease. Our mouse model reflects aspects of the human 
disease, albeit only in the homozygous setting, when wild-
type titin protein is absent. By contrast, the human variant 
is heterozygous, thus the missense and wild-type protein 
co-exist. This caveat is commonly observed for mouse mod-
els of cardiomyopathy variants. For example, missense vari-
ants in Mybpc3 and Csrp3 only display phenotypes in the 
homozygous setting [10, 57], whilst heterozygous mice are 
normal. The vast physiological differences between mice 
and humans, as well as the sedentary lifestyle of laboratory 
mice, are likely to be contributing factors to this difference.
The mild DCM phenotype of our mouse model also 
mirrors the observation that young mice or rats carrying 
pathogenic truncating variants in titin display no overt DCM 
phenotypes [16, 48]. At transcript level, three of the four 
top KEGG pathways in our RNAseq dataset—“Ribosome”, 
“Oxidative Phosphorylation” and “Proteasome “—were 
also in the top four KEGG pathways to be found enriched 
in human cardiac biopsies from DCM patients with titin 
truncating variants, when compared to samples from DCM 
patients without titin truncating variants [56], suggesting 
that our titin missense model shares some molecular simi-
larities with DCM caused by titin truncating variants, at least 
at the transcriptome level.
Careful morphological analysis by HREM failed to find 
evidence of abnormal trabeculation in the mice. Hence, the 
model does not recapitulate the hypertrabeculation in the 
reported family [19]. However, to our knowledge there are 
only few genetic mouse models for hypertrabeculation in 
the adult heart [6, 8], suggesting that this feature of human 
cardiac disease is poorly reflected in mice [42].
Our isolated cardiomyocyte work has underpinned fea-
tures of cardiomyopathy in the mouse model, which appear 
to contradict the whole heart parameters: Isolated cardio-
myocytes are increased in cell size (~ 30%), however we 
failed to detect significant increase in ventricular mass in 
the whole hearts. A possible explanation is that cardiomyo-
cytes make up only 20–35% of the heart (by numbers) [2], 


















Fig. 7  Loss of telethonin in A178D heart and partical restoration 
upon proteasomal inhibition. Top—Cryo-sections of hearts from 
WT mice, stained for telethonin and titin Z-disc epitope T12; nuclei 
are visualised with DAPI. Telethonin is localised at the Z-discs. 
Middle—same staining in A178D hearts treated with vehicle (10% 
dimethyl sulfoxide in 0.9% saline). Telethonin signal is lost from the 
Z-discs. Asterisks indicate non-specific staining of the telethonin 
antibody at the extracellular matrix. Bottom—A178D hearts treated 
with epoxomicin (0.5 mg  kg−1 bodyweight per day for 7 days) show 
partial restoration of telethonin signal at the Z-disc (arrowheads). 
Scale bar represents 25 microns. All mice in this experiment are male 
(n = 2 per group; WT age 116 days, A178D age 115 ± 2 days)
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and that the size difference observed in cells gets “diluted” 
in the whole heart.
To our surprise, contractility and calcium transient meas-
urements in isolated cardiomyocytes were normal; they did 
not reflect the observed reduced systolic dysfunction docu-
mented in vivo by echocardiography. It is worth noting that 
the isolated cardiomyocytes are mechanically unloaded and 
hence cannot recapitulate all aspects of loaded heart perfor-
mance, as demonstrated for other mouse models [38].
Titin phosphorylation was normal when assessed by ProQ 
Diamond stain. However, this assay may not reflect all phos-
phorylation events equally [18] and titin functions can addi-
tionally be regulated by other post-translational events such 
as e.g. glutathionylation [1].
We cannot rule out a secondary contribution of autophagy 
to the degradation of telethonin and Fhl2, as has also been 
described for a Mybpc3 mouse model [51]. Cross-talk 
between the UPS and autophagy is well established for the 
Fig. 8  a Summary of induction 
of a proteo-toxic response in 
1 year old A178D mice assessed 
by Western blotting (Mann–
Whitney U test, n = 6, age WT 
416 ± 2 days, A178D 423 ± 3 
days, all male). b Summary 
of induction of a proteo-toxic 
response in a cohort undergoing 
adrenergic challenge assessed 
by Western blotting. Kruskal–
Wallis followed by Wilcoxon 
rank sum test with Bonferroni 
correction, n = 6, age 120 ± 2 
days, all male. For summary see 
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Table 2  Summary of results 
from Western blots for proteo-
toxic response on the three 
different cohorts
Significant changes of homozygous A178D compared to WT (of same treatment group for Iso/PE chal-
lenge) are indicated; ↑ upregulation, n.s. not significant
For original blots and quantifications see Figs. S29–34
Protein (Transcript) Figure 3 month old Aged (1 year old) Iso/PE challenge
Bag3 S29 n.s. n.s. ↑ (Iso/PE)
Hsp70 (Hspa1a) S30 n.s. n.s. ↑ (Iso/PE)
Hsc70 (Hspa8) S31 n.s. ↑ (also HET) n.s.
αβ-crystallin (Cryab) S32 n.s. ↑ n.s.
Hsp27 (Hspb1) S33 n.s. ↑
Hspb7 S34 n.s. n.s. n.s.
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heart [60], with p62 being a crucial mediator linking both 
protein degrading systems [53].
Despite these limitations and caveats, our A178D mice 
represent a valuable tool to study titin-related cardiomyo-
pathy. To our knowledge, it is the first mouse model of a 
cardiomyopathy-causing titin missense variant and provides 
valuable insights into the role of proteo-toxicity as a con-
tributor to cardiomyopathy. Moreover, it will be of use in 
future studies to molecularly test, for example, the effects 
of environmental factors [58], oligogenic factors or drug 
therapy on disease outcome.
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